EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Icariin Mitigated Non-Alcoholic Fatty Liver Disease Progression via miR-185-3P/CX3CL1 Axis

Wenwen Hong, Ruomei Zhang, Shanzhong Tan

Acta Poloniae Pharmaceutica - Drug Research · 17.06.2026 · 84 (1) · 63-71

DOI: 10.32383/appdr/223954 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Poloniae Pharmaceutica - Drug Research, online erschienen am 17.06.2026. Verfasst von Wenwen Hong und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-alcoholic fatty liver disease (NAFLD) ranks among the most prevalent liver diseases globally. Icariin (ICA) has been shown to improve NAFLD, but the specific molecular mechanisms remain unclear. The study was to probe the underlying mechanisms of ICA in NAFLD. Quantitative real-time PCR (RT-qPCR) was employed to detect gene levels. Enzyme-linked immunosorbent assay (ELISA) was utilized to measure the concentrations of inflammatory factors. The target-binding relationship was validated through a dual-luciferase reporter assay and RNA Immunoprecipitation (RIP) assay. Our findings revealed that ICA dose-dependently decreased the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglycerides (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C), while increasing high-density lipoprotein cholesterol (HDL-C) levels in the NAFLD model. Additionally, it dose-dependently reduced the levels of interleukin-1β (IL-1β), interleukin-6 (IL-6), and interleukin-12 (IL-12), and elevated miR-185-3p expression. In free fatty acids (FFA)-treated HepG2 cells, the miR-185-3p inhibitor attenuated the suppressive effect of ICA on inflammatory factors and its promoting effect on miR-185-3p levels. Fractalkine (CX3CL1) levels were diminished in an ICA dose-dependent manner. In FFA-treated HepG2 cells, silencing miR-185-3p elevated the secretion of inflammatory factors, whereas si-CX3CL1 reversed this effect. ICA alleviated liver damage, lipid metabolism disorders, and inflammatory responses via the miR-185-3p/CX3CL1 axis, thereby slowing the progression of NAFLD.

Zitieren

APA

Hong, W., Zhang, R., & Tan, S. (2026). Icariin Mitigated Non-Alcoholic Fatty Liver Disease Progression via miR-185-3P/CX3CL1 Axis. Acta Poloniae Pharmaceutica - Drug Research, 84(1), 63-71. https://doi.org/10.32383/appdr/223954

Vancouver

Hong W, Zhang R, Tan S. Icariin Mitigated Non-Alcoholic Fatty Liver Disease Progression via miR-185-3P/CX3CL1 Axis. Acta Poloniae Pharmaceutica - Drug Research. 2026;84(1):63-71. doi:10.32383/appdr/223954

BibTeX
@article{Hong2026,
  author = {Hong, Wenwen and Zhang, Ruomei and Tan, Shanzhong},
  title = {Icariin Mitigated Non-Alcoholic Fatty Liver Disease Progression via miR-185-3P/CX3CL1 Axis},
  journal = {Acta Poloniae Pharmaceutica - Drug Research},
  year = {2026},
  volume = {84},
  number = {1},
  pages = {63--71},
  doi = {10.32383/appdr/223954}
}
Kostenlos starten →